Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin

Clinical Trial Description

Patients will receive initial intravenous (IV) echinocandin therapy. Patients who are eligible for randomization will receive SCY-078 500-mg orally, SCY-078 750-mg orally, or standard-of-care. ;

Study Design

See also
Status	Clinical Trial	Phase
Recruiting	`NCT00342589` - New Techniques for Using a Saline Wash as a Diagnostic Tool for Pneumocystis Pneumonia
Completed	`NCT01232504` - Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT	Phase 4
Completed	`NCT00177788` - Voriconazole as Prophylaxis for Liver Transplant Recipients	N/A
Completed	`NCT03667690` - Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis	Phase 3
Completed	`NCT00001790` - Phase I Study of the Safety, Tolerance, and Pharmacokinetics of FK463 in Immunocompromised Children With Fever and Neutropenia	Phase 1
Recruiting	`NCT04157465` - Anti-fungal Strategies in Acute-on-Chronic Liver Failure Patients	N/A
Completed	`NCT00890708` - Therapeutic Drug Monitoring of Voriconazole	N/A
Completed	`NCT00001937` - Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients	Phase 3
Completed	`NCT00001757` - An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections	Phase 3
Recruiting	`NCT01260974` - Caspofungin as Prophylaxis in High Risk Liver Transplantation Recipients	Phase 2
Completed	`NCT00896493` - Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma	Phase 2
Recruiting	`NCT00673348` - Therapeutic Drug Monitoring (TDM) of Voriconazole and Correlation With CYP2C19 Genotype in Korean Populations	N/A
Recruiting	`NCT04368559` - Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation	Phase 3
Completed	`NCT00413218` - Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections	Phase 3
Completed	`NCT04265521` - Study With BioCool Footcare in Subjects With Tinea Pedis Interdigitalis and Heel Cracks, Calluses and/or Dry Feet	N/A
Completed	`NCT01254318` - Assessment of the Fungal Infection Incidence Across Canada for High Risk Subjects With Hematological Disease (Study P07501)	N/A
Completed	`NCT02733432` - RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections	Phase 2
Completed	`NCT00005912` - Voriconazole to Prevent Systemic Fungal Infections in Children	Phase 1
Completed	`NCT02734862` - CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension	Phase 2
Withdrawn	`NCT00704951` - Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections in Immuncompromised Patients in Austria (Study P05532)(WITHDRAWN)	N/A

NCT number	NCT02244606
Study type	Interventional
Source	Scynexis, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	September 2014
Completion date	August 2016

Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms